NCT02628067 2025-09-22KEYNOTE 158Merck Sharp & Dohme LLCPhase 2 Active not recruiting1,609 enrolled 5 FDA
NCT04280081 2025-04-20LIBRETTO-321Eli Lilly and CompanyPhase 2 Active not recruiting77 enrolled 13 charts
NCT00537095 2024-04-19Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid CancerSanofiPhase 2 Completed164 enrolled 10 charts
NCT02702388 2021-11-24A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety ProfileEisai Inc.Phase 2 Completed241 enrolled 32 charts
NCT00124527 2021-06-16Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid CancerEisai Inc.Phase 2 Completed35 enrolled
NCT01728623 2020-08-14A Study of E7080 in Subjects With Advanced Thyroid CancerEisai Inc.Phase 2 Completed51 enrolled 15 charts
NCT00784303 2020-04-22Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by HistologyEisai Inc.Phase 2 Completed117 enrolled 19 charts
NCT02614495 2020-02-13Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid CarcinomaHutchmedPhase 2 Completed66 enrolled
NCT00896454 2018-10-17Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum CalciumAmgenPhase 2 Completed33 enrolled 22 charts
NCT00098345 2018-05-07Efficacy and Tolerability of ZD6474 in Patients With Thyroid CancerSanofiPhase 2 Completed40 enrolled 12 charts
NCT02114658 2017-08-03Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma PatientsBayerPhase 2 Completed18 enrolled
NCT00358956 2017-01-30A Study To Assess ZD6474 (ZACTIMAâ„¢) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid CancerSanofiPhase 2 Completed19 enrolled 10 charts
NCT00389441 2013-11-25Study Of AG-013736 In Patients With 131I-Refractory Thyroid CancerPfizerPhase 2 Completed52 enrolled 9 charts
NCT00121628 2013-10-09A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid CancerAmgenPhase 2 Completed184 enrolled
NCT00094055 2012-06-26Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid CancerPfizerPhase 2 Completed60 enrolled 9 charts